AVN-101 (hydrochloride)

AVN-101 is a multimodal receptor antagonist.¹ It is an antagonist of the serotonin (5-HT) receptor subtypes 5-HT₇, 5-HT_2C, 5-HT_2A, and 5-HT₆ (K_is = 0.153, 1.17, 1.56, and 2.04 nM, respectively). It is selective for these receptors over 5-HT_2B, 5-HT_5A, 5-HT_1A, and 5-HT_1B receptors (K_is = 10.6, 20.8, 61, and 720 nM, respectively). It is also an antagonist of α_2A-, α_2B-, α_2C-, α_1B-, α_1A-, and α_1D-adrenergic receptors (K_is = 0.41, 1.77, 3.55, 9.4, 18.9, and 30.2 nM, respectively), as well as histamine H₁ and H₂ (K_is = 0.58 and 89 nM, respectively), but not H₃, receptors. AVN-101 (0.2, 1, and 5 mg/kg) increases the time spent in the open arms of the elevated plus maze in mice. It also reduces immobility in the forced swim test and prevents scopolamine-induced amnesia in a passive avoidance test in mice when administered at a dose of 0.05 mg/kg.

WARNING This product is not for human or veterinary use.

1. Ivachtchenko, A.V., Lavrovsky, Y., and Okun, I. AVN-101: A multi-target drug candidate for the treatment of CNS disorders. J. Alzheimers Dis. 53(2), (2016).